Find Academic Supervisors

Timothy BredyView profile

Associate Professor

• Epigenetics
• Fear-Related Memory
• RNA Biology
• +6 more

Associate Professor Timothy Bredy is a leading figure in cognitive neuroepigenetics at the Queensland Brain Institute (QBI) , focusing on how epigenetic modifications and RNA dynamics regulate fear-related memory and psychiatric disorders like PTSD. His research explores the interplay between environmental experiences and genomic activity, particularly through non-coding RNA and DNA methylation. University: University of Queensland School: Faculty of Health, Medicine and Behavioural Sciences Role: Professorial Research Fellow and Group Leader Research Interests span epigenetic mechanisms in memory formation, RNA modifications in synaptic plasticity, and therapeutic applications for anxiety disorders. He pioneered discoveries linking dynamic DNA structures (e.g., G-quadruplexes) and RNA methylation to memory stability. Recent Work includes studies on RNA-based therapeutics, stress-induced epigenetic inheritance, and synaptic long noncoding RNA activity. His scientific awards encompass NHMRC and ARC grants for neuroepigenetics research. Key Collaborators: Paul Marshall, Esmi Zajaczkowski Labs: Bredy Laboratory at QBI

• Genomics
• Non-coding RNA research
• Phenotype-genotype relationships
• +7 more

Professor Marcel Dinger is a prominent academic and researcher currently serving as Professor and Head of School for Biotechnology and Biomolecular Sciences at UNSW Sydney. With over 20 years of experience in genomics, he has established himself as a leading figure in both academic and entrepreneurial spheres within the field. He has published 153 papers with over 24,000 citations and maintains an h-index of 61 on Google Scholar. His leadership extends beyond academia as he serves as President of the Australasian Genomics Technologies Association (AGTA) and holds director positions at Pryzm Health and the National Centre for Indigenous Genomics (NCIG). Professor Dinger's research laboratory focuses on establishing new links between phenotype and genotype, particularly examining rare and complex diseases in relation to underexplored regions of the genome including pseudogenes, repetitive elements, non-canonical DNA structures, and noncoding RNAs. His work harnesses population-scale genomic datasets and sophisticated data science methods to bring an objective perspective to understanding how the genome stores information and how it is transacted in biology. His research interests span genomics, non-coding RNA biology, clinical applications of genomic medicine, and the development of computational approaches for analyzing complex genomic data. Analysis of Professor Dinger's recent publications reveals a strong emphasis on non-coding RNA research, particularly long noncoding RNAs and their roles in disease mechanisms. His work spans cancer genomics, neurological disorders, and fundamental genomic mechanisms including DNA secondary structures like i-motifs and G-quadruplexes. His research combines experimental approaches with advanced bioinformatics to address fundamental questions in genomic medicine and has significant translational implications for disease diagnosis and treatment. Highly Cited Researcher in Cross-Field category (2019, 2020, 2021) Fellow of the Faculty of Science (Research), Royal Society of Pathologists of Australasia (2016) NHMRC Career Development Award (2010) Queensland Government Smart Futures Fellowship (2009) Foundation of Research, Science and Technology New Zealand Postdoctoral Fellowship (2005) Professor Dinger has been instrumental in establishing and leading several significant research initiatives including Genome.One, one of the first companies globally to provide clinical whole genome sequencing services, and the Kinghorn Centre for Clinical Genomics at the Garvan Institute of Medical Research. His entrepreneurial experience includes founding four biotechnology and IT startups. He serves on multiple governance boards including the National Centre for Indigenous Genomics, focusing on using genomics to improve health outcomes for Australia's First Peoples. His laboratory at UNSW continues to advance our understanding of genomic regulation and its implications for human health and disease.

Laura LeightonView profile

Research Fellow

• RNA Biology
• mRNA Therapeutics
• Gene Therapy
• +3 more

Dr. Laura Leighton is a Postdoctoral Research Fellow in the mRNA Sciences group at the Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland. Her research focuses on RNA biology, particularly the functional characterization of RNA molecules and their roles in cancer therapy and neurological processes. She leads the development of mRNA-based therapeutics for liver cancer, leveraging lipid nanoparticle (LNP) delivery systems to target intracellular cancer proteins. Dr. Leighton holds a PhD from the Queensland Brain Institute (2021), where her work, supported by the Westpac Future Leaders Scholarship, explored small noncoding RNAs in fear-related learning and memory. She completed her postdoctoral training under Dr. Seth Cheetham at AIBN in 2023. Her educational background includes a Bachelor of Science and Bachelor of Science (Honours) from The University of Queensland. Her research interests integrate molecular biology, neuroscience, and translational medicine, with a focus on RNA modifications (e.g., m6A), long noncoding RNAs, and the epigenetic regulation of memory processes. Key themes in her work include fear extinction mechanisms, synaptic plasticity, and the application of mRNA therapeutics in cancer treatment. Dr. Leighton’s articles consistently explore RNA-driven mechanisms in memory and disease. Recent work highlights the role of DNA G-quadruplex structures in memory regulation, the interplay between stress hormones and sperm RNA dysregulation, and the synthesis of novel long noncoding RNAs (e.g., ADRAM) that drive fear extinction. Her findings bridge basic neuroscience and clinical applications, emphasizing RNA’s dynamic role in health and disease. Awards: Westpac Future Leaders Scholarship (2017) Grants: TdC Mid Career Grant (Targeting liver cancer with mRNA therapies), Prader Willi Syndrome Research Grant (2022–2024) She is actively involved in supervising research students and contributes to the development of advanced drug delivery systems targeting liver cancers. Her lab is part of AIBN’s mRNA Sciences team, collaborating on projects that translate RNA-based discoveries into clinical solutions.

Paul MarshallView profile

Researcher

• Neuroscience
• Epigenetics
• RNA Biology
• +3 more

Dr. Paul Marshall is a Researcher at the Queensland Brain Institute, The University of Queensland, supported by an NSERC Scholarship. His work focuses on neuroepigenetic mechanisms underlying learning and memory, with expertise in RNA biology, DNA structure dynamics, and fear extinction processes. He completed his PhD in 2020 at the Queensland Brain Institute, exploring dynamic DNA structure states and their role in memory. His research integrates cutting-edge technologies to study noncoding RNAs, epigenetic modifications (e.g., m6A, Z-DNA), and their impact on synaptic plasticity and cognitive functions. Key contributions include identifying the role of DNA G-quadruplex in transcriptional control, the function of long noncoding RNAs in fear extinction, and mechanisms linking RNA editing (via ADAR1) to memory consolidation. His findings bridge molecular biology with behavioral neuroscience, advancing understanding of how genetic and epigenetic factors influence cognitive processes. Publications highlight collaborations with Timothy Bredy and others, emphasizing interdisciplinary approaches to unravel neural mechanisms. No awards are explicitly listed, but his work is recognized in high-impact journals like Nature Neuroscience and Cell Reports .

• Cancer
• Endocrinology
• Surgical Education
• +3 more

Associate Professor Anthony Glover is a practicing specialist endocrine surgeon and surgical oncologist at the University of Sydney. He serves as Director of the Master of Surgery Program and holds academic affiliations with the Northern Clinical School (University of Sydney) and St Vincent’s Clinical School (UNSW). His clinical practice focuses on thyroid and parathyroid disease at Kolling Institute St Leonards, Bondi Junction, and St Vincent's Clinic. Education: MBBS, PhD, FRACS Leadership: Coordinator for postgraduate surgical coursework programs and Senior Instructor for the Care of the Critically Ill Surgical Patient Course (RACS) Research interests center on thyroid cancer biology, surgical education, and improving clinical outcomes through genomic analysis. Key projects include molecular profiling of advanced thyroid cancers and development of surgical competency frameworks. He leads the Thyroid Cancer Research Group and contributes to international registries like the Australian New Zealand Thyroid Cancer Registry. Over 50 peer-reviewed articles span surgical innovation, molecular pathology, and clinical outcomes. Notable works include validation of the International Medullary Thyroid Carcinoma Grading System and assessment of BRAFV600E mutation specificity in papillary thyroid carcinoma. Awards: 2022 NSW Premier’s Cancer Research Fellowship, NHMRC Neil Hamilton Fairley Fellowship (2016-2020) Grants: NHMRC Development Grants, Cancer Institute NSW funding Active in surgical education through development of assessment modules for General Surgeons Australia and leadership roles in ANZES and the Surgical Education Research and Training (SERT) Institute.

• Gene Regulation
• Nucleic Acids
• G-quadruplexes
• +4 more

Nicole Smith is a Senior Lecturer at the University of Western Australia (UWA) in the School of Molecular Sciences and a member of the Australian Centre for RNA Therapeutics in Cancer. Her research focuses on non-canonical nucleic acid structures, including G-quadruplexes and i-Motifs, in diseases such as cancers, dementias, and neurodegenerative disorders. She holds a PhD from UWA (2010) and has conducted postdoctoral research at institutions like the Institut Européen de Chimie et Biologie (Bordeaux, France) and The Australian National University. Education: B.Sc. (Biochemistry & Chemistry, University of Sydney), PhD (University of Western Australia) Postdoctoral roles: ANR Fellowship (IECB, France), ANU (Australia) Her research interests span Biochemistry, Chemical Biology, Biophysics, and Genomics. She investigates the role of nucleic acid structures in disease mechanisms, with a focus on therapeutic applications. Key projects include targeting G-quadruplex DNA in Alzheimer’s and breast cancer, and developing nanotechnology-based therapies for neurotrauma. Dr. Smith has secured over 28 grants, including a NHMRC Dementia Fellowship (2017), National Breast Cancer Foundation Innovator Grant (2017), and leadership in the ARC Training Centre for Next-Gen Biomedical Analysis. Her work contributes to UN SDGs 3 (Good Health) and 9 (Industry Innovation). She has supervised numerous students, including 6 PhD graduates, 10 Masters students, and 9 Honours students, alongside exchange scholars from the University of Bath and others. Awards include the Healy Research Collaboration Award (2015) and a visiting professorship at Università Degli Studi di Padova (2021). Labs/Teams: Australian Centre for RNA Therapeutics in Cancer, collaborations in nanomedicine, neuroscience, and drug delivery.

Emily OatesView profile

Senior Lecturer

• Medical Genomics
• Neurogenetics
• Neuromuscular Disorders
• +6 more

Dr. Emily Oates is a Senior Lecturer in Medical Genomics at the University of New South Wales (UNSW), School of Biotechnology and Biomolecular Sciences. She serves as head of the UNSW Medical Genomics Group and works as a neurogenetics consultant for The Sydney Children's Hospital Network. With over 14 years of clinical experience, Dr. Oates specializes in the diagnosis and management of childhood-onset neuromuscular disorders. Her research focuses on the discovery of new human disease genes and analysis of clinical, RNA transcript, protein, and tissue-level impacts of disease-causing mutations, particularly within the TTN gene (titin) and related disorders (titinopathies). As leader of the UNSW Medical Genomics Group, she works to increase genetic diagnosis rates, advance understanding of clinical characteristics and pathogenesis of genetic disorders, and develop potential new therapies. Dr. Oates' recent publications demonstrate a strong focus on neuromuscular genomics, with particular emphasis on titin-related disorders, RNA sequencing applications in diagnostics, and the molecular characterization of congenital myopathies. Her work bridges clinical practice with genomic research, developing diagnostic approaches that have significantly improved diagnosis rates for neuromuscular conditions. Her areas of expertise include genetics, genomics, transcriptomics, neuromuscular disorders, rare diseases, RNA sequencing, whole genome sequencing, diagnostics and disease characterization, striated muscle biology, and TTN (titin) disorders. Based in Room 320C, Level 3, Biological Sciences North Building D26 at UNSW, Dr. Oates maintains an active research program that combines clinical neurogenetics with cutting-edge genomic technologies to improve diagnosis and understanding of complex neuromuscular conditions.

Gene Hart-SmithView profile

Researcher

• Mass Spectrometry
• Protein Interactions
• Molecular Systems Biology
• +7 more

Dr. Gene Hart-Smith is a Technology Manager for Protein Interactions at the Australian Proteome Analysis Facility (APAF), affiliated with Macquarie University. He holds a PhD in Chemistry from the University of New South Wales (UNSW) and has extensive postdoctoral experience, including ARC-funded fellowships (2011–2018). His expertise lies in mass spectrometry applications for biological systems, particularly protein interactions and post-translational modifications. Education: PhD in Chemistry, UNSW (2006–2010) Bachelor of Engineering (Industrial Chemistry, Honours Class 1), UNSW (2001–2005) Research Focus: Hart-Smith’s work integrates molecular systems biology and network theory to study biomolecular interaction networks. Key areas include protein modifications (e.g., arginine methylation), X chromosome inactivation in marsupials, and applications to diseases like Alzheimer’s. He develops proteomics methodologies for environmental and medical research, such as root architecture studies in rice and concussion biomarker identification in children. Recent Research Trends: His articles (2024–2021) highlight advancements in protein interactome mapping, drug discovery, and biomarker development. Techniques like mass spectrometry, ion mobility, and co-fractionation are central to his methodologies. Awards: ARC DECRA Fellowship (2015–2018) ARC Australian Postdoctoral Fellowship (2011–2014) Collaborations: Hart-Smith collaborates globally on projects ranging from archaeological bone analysis to cancer therapy development. His work bridges fundamental research and applied solutions in sustainability and healthcare.

Tao LiuView profile

Associate Professor

• Oncology and Carcinogenesis
• Cancer Cell Biology
• Cancer Genetics
• +9 more

Associate Professor Tao Liu is a prominent cancer researcher at the Children's Cancer Institute, which operates within the Lowy Cancer Research Centre at the University of New South Wales Australia (UNSW Australia). His work focuses on understanding the molecular mechanisms of cancer development and identifying novel therapeutic targets through epigenetic regulation. Dr. Liu holds qualifications including BMed, MMed, and PhD, which have established his foundation in medical science and research methodology. His educational background has prepared him for his current research in oncology and molecular biology. Dr. Liu's research program centers on: Transcriptional modulation of oncogene and tumour suppressor gene expression Epigenetic mechanisms including histone modifications and RNA methylation Role of BET bromodomain proteins and super-enhancers in cancer CDK7 and other kinase inhibitors for cancer therapy Myc oncoprotein regulation and stability mechanisms Long noncoding RNAs as therapeutic targets With 132 journal articles and numerous conference contributions to his name, Dr. Liu has established himself as a significant contributor to cancer research. His work primarily investigates how epigenetic regulators control gene expression in cancer cells and how these mechanisms can be targeted therapeutically. Dr. Liu serves in multiple editorial capacities including Specialty Chief Editor for Frontiers in Oncology and Associate Editor for Frontiers in Genetics. He is an active member of the American Association for Cancer Research and serves on the Advisory Board of the international Advances in Neuroblastoma Research Association. Dr. Liu currently supervises PhD and Honours students in cancer research and has secured substantial funding from prestigious organizations including the National Institutes of Health USA, US Department of Defense, National Health & Medical Research Council, Cancer Council NSW, Tour de Cure, and Neuroblastoma Australia. His laboratory at the Children's Cancer Institute within the Lowy Cancer Research Centre focuses on translating basic molecular discoveries into potential cancer therapies, with particular emphasis on epigenetic drug targets and RNA-based therapeutics.

• Biomedical Engineering
• Dentistry
• Genetics
• +3 more

Dr. Jaikrishna Balakittnen serves as a Research Fellow at the Institute for Biomedicine and Glycomics within Griffith Sciences at Griffith University, holding this position since 2024. His work focuses on developing non-invasive diagnostic methods for oral cancer through salivary biomarker analysis. His research spans Biomedical Engineering, Dentistry, Genetics, Biochemistry and Cell Biology, Cancer Genetics, and Oncology and Carcinogenesis. Key investigations include miRNA profiling and noncoding RNA mechanisms in oral cancer pathogenesis, with emphasis on translating molecular discoveries into clinical diagnostics. Recent publications reveal a strong trend toward liquid biopsy applications in oncology, particularly saliva-based miRNA diagnostics. The 2024 International Journal of Oral Science article established a novel predictive miRNA profile, while the 2022 WIREs RNA review synthesized current knowledge on noncoding RNAs in oral cancer, both demonstrating significant research impact with 26 and 29 citations respectively. No scientific awards were documented in the available records. Though no students are listed, Dr. Balakittnen currently serves as a chief investigator on an Australian & New Zealand Association of Oral & Maxillofacial Surgeons (ANZAOMS) grant titled 'What happens to the expression of salivary microRNA of oral potentially malignant lesions after excision?' (2024-2025), valued at $29,396, examining post-excision biomarker dynamics with collaborators Punyadeera C, Breik O, and Ekanayake Weeramange C. He operates within the Institute for Biomedicine and Glycomics research ecosystem at Nathan Campus (Building N75), contributing to Sustainable Development Goals 3 (Good Health and Well Being) and 9 (Industry, Innovation and Infrastructure) through translational cancer research.

Mazhar HussainView profile

Research Fellow

• Microbiology
• Virology
• Molecular Biology
• +5 more

Dr. Mazhar Hussain is a Postdoctoral Research Fellow at the School of Agriculture and Food Sustainability, Faculty of Science, The University of Queensland. His research focuses on the molecular interactions between mosquitoes, viruses, and bacterial symbionts, particularly examining how microRNAs regulate these complex relationships. Dr. Hussain completed his PhD at The University of Queensland in 2010 with a thesis titled "ASCOVIRUS INFECTION: Role of microRNAs and viral encoded genes in gene silencing and pathogenesis." His academic journey has centered on understanding molecular mechanisms in insect-virus interactions, with a particular emphasis on mosquito vectors of human diseases. Dr. Hussain's research primarily investigates the intricate relationships between Aedes aegypti mosquitoes, Dengue virus, and the bacterial symbiont Wolbachia . His work explores how microRNAs regulate viral replication, mosquito immunity, and vector competence. He has made significant contributions to understanding how Wolbachia blocks viral replication in mosquitoes, which has important implications for controlling arboviral diseases. His research spans molecular biology, virology, and entomology, with a focus on identifying key molecular players that determine vector competence and potential targets for disease control strategies. Dr. Hussain's publication record shows a consistent trajectory of high-impact research, with numerous publications in prestigious journals including PNAS, mBio, and Journal of Virology. His recent work (2023-2025) continues to advance our understanding of mosquito-virus-symbiont interactions, particularly focusing on RNA-based regulatory mechanisms. ARC Discovery Early Career Researcher Award (2012-2015): "Investigating the interaction of microRNAs-Wolbachia-Dengue virus in the mosquito vector, Aedes aegypti" Dr. Hussain serves as an Associate Advisor for PhD students, currently supervising research on "Role of Juvenile Hormone and microRNA on the Regulation of Aedes aegypti Fecundity and Dengue Virus Replication" and previously supervised a 2017 PhD project on "Exploring the molecular mechanism(s) involved in Wolbachia-Aedes aegypti-dengue virus interactions." His laboratory work primarily focuses on molecular techniques to study gene expression, protein interactions, and viral replication in mosquito cell lines and whole organisms.

Paul YehView profile

Academic

• Haematology
• Haematological Malignancies
• Clonal Haematopoiesis
• +6 more

Dr Paul Yeh is a Senior Research Fellow and clinician-scientist at Monash Health and Monash University, with dual appointments in haematology and clinical sciences. He leads the Blood Cancer Biomarkers Laboratory, focusing on molecular biomarkers to improve outcomes for patients with haematological malignancies. Yeh holds a PhD from the University of Melbourne and has received prestigious awards including the EHA/ASH TRTH scholar award and NHMRC/MRFF Emerging Leadership Fellowship. His clinical expertise spans molecular haematology and myeloid neoplasms, complementing his research in genomics, clonal haematopoiesis, and biomarker development. Education: PhD: Molecular Monitoring in Haematological Malignancies (University of Melbourne, 2018) MBBS & BMedSci: University of Melbourne (2005) Research Interests: Yeh’s lab prioritizes translational research in blood-based molecular biomarkers, with a focus on: Next-generation sequencing for haematological malignancies Clonal haematopoiesis and its clinical implications Myeloid leukaemia and myeloproliferative disorders Multi-omics approaches in biomarker discovery Recent work highlights include validation of saliva-derived DNA for clonal haematopoiesis detection and challenges in FLT3-mutated AML treatment response assessment. Active clinical trials focus on BET inhibitors (molibresib) and JAK inhibitors in myelofibrosis. Awards: EHA/ASH TRTH Scholar Award (2018) NHMRC/MRFF Emerging Leadership Fellow (current) Gilead Fellowship Research Grant (2019) Grants & Projects: Yeh leads 14 active research projects, including Phase 3 trials evaluating Bomedemstat and Navtemadlin in myeloproliferative neoplasms. His work integrates clinical leadership in molecular pathology with translational research. Labs & Teams: Head of the Blood Cancer Biomarkers Laboratory, collaborating on multi-institutional studies to advance precision medicine in haematological cancers.

Dylan KiltschewskijView profile

Research Fellow

• Bioinformatics
• Epigenetics
• Genomics
• +5 more

Roles & Affiliations: Dylan Kiltschewskij is a Postdoctoral Research Fellow in the Molecular Neurobiology department at the University of Newcastle's School of Biomedical Sciences and Pharmacy. He also holds a Casual Academic appointment at the same institution. His primary affiliation is with Professor Murray Cairns’ Complex Disorder Group. Education: Bachelor of Biomedical Science (First Class Honours), University of Newcastle (2015) PhD in Medical Genetics, University of Newcastle Research Interests: Dylan’s work focuses on the intersection of neuroscience, genetics, and psychiatric disorders. He employs multidimensional molecular techniques, systems biology, and statistical genetics to investigate: Genome-wide association studies (GWAS) for psychiatric disorder mechanisms Epigenetic profiling (DNA methylation) for schizophrenia risk stratification Noncoding RNA (microRNA, circRNA) roles in neuronal differentiation Drug repurposing opportunities through biochemical exposure studies Publications Trends: His 15 most recent articles (2020–2025) emphasize: Cardiovascular toxicity in cancer therapies Cortical anatomy-genetic biomarker correlations Federated neuroimaging analysis in psychiatric disorders Molecular mechanisms of neurodevelopmental disorders Awards: 2016 Australian Postgraduate Award 2015 Faculty of Health and Medicine Medal Multiple undergraduate prizes (2014–2015) Grants & Supervision: Principal supervisor for a current PhD student researching cancer genetics Total grant funding: $39,000 across 7 grants (2018–2022) Highlighted grant: 'Utilising Epigenetic Risk for Schizophrenia as a Platform for Precision Medicine' ($10,000, 2022) Labs/Teams: Active in the Cairns lab, focusing on psychiatric disorder mechanisms and precision medicine applications.

• Neurofibromatosis Type 1
• Rare Genetic Diseases
• 2D Facial Recognition Technology
• +4 more

Professor Tracy Dudding-Byth AM is a Consultant Clinical Geneticist in the NSW Genetics of Learning Disability (GOLD) Service at Hunter Genetics, Australia. She holds a conjoint professorship at the University of Newcastle within the School of Medicine and Public Health, Department of Medical Genetics. Her work bridges clinical research and patient advocacy, focusing on neurofibromatosis type 1 (NF1) and rare genetic diseases. PhD, University of Newcastle Co-founder, Rare Voices Australia Her research explores genetic modifiers in NF1 severity and the application of 2D facial recognition technology (FaceMatch) for diagnosing syndromic intellectual disability. She leads a $1.6M Medical Research Future Fund project on cutaneous neurofibromas and has contributed to RNA diagnostics standardization via the SpliceACORD consortium . The FaceMatch platform integrates computer vision with genomic data to enhance diagnostic accuracy across age groups. Her studies span neurogenetic disorders , X-linked intellectual disability , and RNA splicing mechanisms , with collaborative links to the Max Planck Institute and Wellcome Trust Sanger Institute. 2021 Research Australia Health and Medical Research Data Innovation Award 2015 HCRF Research Mentor of the Year 2024 Member of the Order of Australia (AM) She supervises 3 higher-degree research students in rare disease studies and mentors medical students in case report publication. Her community roles include the Medical Advisory Committee of the Steve Waugh Foundation for rare disease advocacy.

• Genetics
• Intellectual Disability
• X Chromosome Disorders
• +4 more

Dr. Anna Hackett is a Conjoint Senior Lecturer in the School of Biomedical Sciences and Pharmacy at the University of Newcastle, specializing in Medical Genetics. With over two decades of research experience, her work primarily focuses on X-linked intellectual disability disorders, genetic diagnostics, and the molecular mechanisms underlying neurodevelopmental conditions. Her research interests encompass a wide range of topics within medical genetics, including X chromosome disorders, noncoding variants in intellectual disability, genomic diagnostics, and the molecular pathways involved in neurodevelopmental disorders. Dr. Hackett has made significant contributions to understanding the genetic basis of X-linked intellectual disability through the identification of novel genes and variants. Analysis of her recent publications reveals a strong focus on advanced genomic technologies for diagnosing intellectual disability, with particular emphasis on X-linked disorders. Her work spans from basic molecular mechanisms to clinical applications, demonstrating a translational research approach that bridges laboratory findings with patient care. She has been instrumental in developing and applying next-generation sequencing techniques for improved diagnostic yield in genetic disorders. Dr. Hackett maintains an active research program with extensive collaborations across multiple institutions in Australia and internationally. Her work has contributed significantly to the understanding of X-linked intellectual disability mechanisms, genomic diagnostics, and the clinical implications of genetic variants. She is frequently involved in large-scale collaborative studies that combine clinical expertise with advanced genomic technologies to improve diagnosis and understanding of genetic disorders.